Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
Public ClinicalTrials.gov record NCT02652624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), or atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed HIV-1 infected women.
Study identification
- NCT ID
- NCT02652624
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 472 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2016 (Actual)
- Primary completion
- Oct 9, 2017 (Actual)
- Completion
- Nov 26, 2018 (Actual)
- Last update posted
- Mar 4, 2020
2016 – 2018
United States locations
- U.S. sites
- 29
- U.S. states
- 10
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Stamford | Connecticut | 6902 | — |
| Not listed | Washington D.C. | District of Columbia | 20009 | — |
| Not listed | Washington D.C. | District of Columbia | 20037 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Ft. Pierce | Florida | 34982 | — |
| Not listed | Miami | Florida | 33133 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Orlando | Florida | 32803-1851 | — |
| Not listed | Tampa | Florida | 33607 | — |
| Not listed | Tampa | Florida | 33614 | — |
| Not listed | West Palm Beach | Florida | 33401 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Savannah | Georgia | 31401 | — |
| Not listed | Springfield | Massachusetts | 01105 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Newark | New Jersey | 07102 | — |
| Not listed | Great Neck | New York | 11021 | — |
| Not listed | The Bronx | New York | 10467 | — |
| Not listed | Charlotte | North Carolina | 28207 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Bellaire | Texas | 77401 | — |
| Not listed | Dallas | Texas | 75208 | — |
| Not listed | Dallas | Texas | 75219 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Harlingen | Texas | 78550 | — |
| Not listed | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02652624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02652624 live on ClinicalTrials.gov.